The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...
The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...
Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors. FDA approves an all-oral treatment for newly ...
Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and ...
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could ...
Selpercatinib (Retevmo), a selective oral RET inhibitor, demonstrated durable antitumor activity and a manageable safety ...
Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...
New research highlights nivolumab AVD as a promising new standard of care for advanced Hodgkin lymphoma, showing improved survival rates and tolerability. A study reveals the gut microbiome's role in ...
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether ...
Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results